fashion -WSS

fashion

author：Wikipedia 2025-09-02 09:56:06 - browse：857

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Elisabeth Bik tackles the widespread issue of research misconduct

hotspot

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

Physician executives need more than on

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Ohio train derailment: Experts on toxic chemical risks

CDC advisory group OKs chikungunya vaccine

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

focus

fashion

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why Charlie Gard's case is so disturbing to Americans

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA authorizes Novavax’s updated Covid

Duchenne breakthrough therapy leaves behind pioneering families

NEJM study measures Covid brain fog, impact on IQ

In Memoriam: Notable people who died in 2023

Stroke deaths set to near 10 million globally by 2050

Guidelines to prevent youth baseball injuries need more muscle

Colorectal cancer study finds potential in overlooked immune cell

hotspot

The future of health care in the House

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Redefining sustainability for the pharmaceutical industry

The future of health care in the House

Bill would stop addiction treatment from triggering child abuse inquiry

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

hotspot

hotspot

leisure time